Related Experiment Video
Updated: May 11, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
Published on: February 15, 2022
C3 glomerulopathy
Aude Servais1, Laure-Hélène Noël, Véronique Frémeaux-Bacchi
1Department of a Nephrology, Service de Néphrologie adultes, Hôpital Necker, 149, rue de Sèvres, FR–75015 Paris, France. aude.servais@nck.aphp.fr
Insights
C3 glomerulopathy, a group of rare kidney diseases like dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), involves complement alternative pathway (AP) dysregulation. Therapeutic inhibition of complement C3 and C5 offers future treatment prospects.
Area of Science:
- Nephrology
- Immunology
- Genetics
Background:
- C3 glomerulopathy is a classification of rare glomerulonephritis, including dense deposit disease (DDD) and C3 glomerulonephritis (C3GN).
- Histological hallmarks include glomerular deposition of C3, primarily in the mesangium and along the glomerular basement membrane (GBM).
- The complement alternative pathway (AP) plays a crucial role, with identified acquired or genetic abnormalities.
Purpose of the Study:
- To review the classification, pathogenesis, clinical presentation, and therapeutic perspectives of C3 glomerulopathies.
- To highlight the role of complement alternative pathway dysregulation and genetic factors.
- To discuss the current understanding and future directions in managing these rare kidney diseases.
Main Methods:
- Review of existing literature on C3 glomerulopathy, focusing on pathogenesis, genetics, clinical features, and treatment.
- Analysis of histological findings, complement pathway abnormalities, and genetic associations.
- Synthesis of information regarding clinical presentation, disease progression, and therapeutic strategies.
Main Results:
- Low serum C3 with normal C4 is a common laboratory finding.
- C3 nephritic factor (C3NeF) is implicated in acquired AP dysregulation, found in 80% of DDD and 45% of C3GN patients.
- Mutations in complement regulatory proteins (CFH, CFI, C3) and genetic variants (SNPs in CFH, C3, CFHR5) are associated with disease development.
Conclusions:
- C3 glomerulopathies are characterized by complement alternative pathway dysregulation, with varying genetic and acquired causes.
- These diseases present with diverse renal manifestations and have a high risk of progression to end-stage renal disease (ESRD) and graft failure post-transplant.
- Therapeutic strategies are evolving, with a focus on inhibiting complement components C3 and C5, and potential benefits from recombinant factor H or plasma exchange in specific deficiencies.
Abstract:
C3 glomerulopathy is a recent disease classification comprising several rare types of glomerulonephritis, including dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). The most common histological feature in these diseases is the presence of glomerular deposition of C3 within the mesangium and along the glomerular basement membrane (GBM) in the subendothelial area or within the GBM. The key role of complement alternative pathway (AP) in these disorders has been recently shown with the identification of acquired or genetic abnormalities. Low serum C3 level but normal C4 is a common finding. The acquired AP dysregulation in DDD and C3GN may be first induced by C3 nephritic factor (C3NeF). C3NeF activity is found in approximately 80% of patients with DDD and in 45% of patients with C3GN. The correlation with the complement is further supported by the detection of homozygous or heterozygous mutations in the regulatory complement proteins factor H (CFH), factor I (CFI), or C3. The genetic background of the patients may also influence the disease manifestation since common genetic variants including single nucleotide polymorphisms in the CFH, C3 and CFHR5 genes are associated with DDD and one at-risk MCP haplotype have been found to be significantly increased in C3GN. C3 glomerulopathies can present over a broad age range. DDD is more often diagnosed in children and age at diagnosis is significantly higher for patients with C3GN. Presenting features comprise any of proteinuria, hematuria, hypertension and renal failure. These glomerulonephritides are associated with chronic deterioration of renal function, leading to ESRD within 10 years of the diagnosis in 36-50% of patients. Outcomes of renal transplantation are characterized by histological recurrence which may contribute to increased rates of allograft failure. Administration of recombinant FH if it becomes available or replacement of FH via plasma exchange may be efficacious in the cases of FH deficiency. However, therapeutic inhibition of complement C3 and C5 is the main perspective.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous capillaries...
Glaucoma: Overview
Nephrotic Syndrome I : Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cerebral Edema ll: Pathophysiology

